Kate Sheridan

@sheridan_kate

Reporter at , covering Boston/biotech/venture capital. Formerly at , . DM for Signal, opinions are mine, etc.

Boston, MA
statnews.com/staff/kate-she…
Vrijeme pridruživanja: prosinac 2010.
118 fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @sheridan_kate

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @sheridan_kate

  1. Prikvačeni tweet
    9. srp 2019.

    Also, today (July 9) happens to be my one-year anniversary on staff at STAT! Here comes a thread of some of the work I've done since I've been here...

    6 replies 2 proslijeđena tweeta 78 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    prije 32 minute

    Re-upping this in light of today's Merck news. The de-90s-fication of pharma continues to be a huge theme. My prediction (barring any major policy changes) is that all big pharma companies are going to look like big biotech within three years.

    Novartis, Merck interestingly also seem to be moving in this direction. Will the future of pharma look more like biotech?
    2 proslijeđena tweeta 5 korisnika označava da im se sviđa
    Poništi
  3. proslijedio/la je Tweet
    prije 3 sata

    Really interesting new health-tech company. Took a deep dive into Verana Health. Think Flatiron, but focused on eyes and brains, not cancer. And, here's the big thing: working directly w/ medical societies. Impressive team, lots to watch going forward.

    1 reply 15 proslijeđenih tweetova 30 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  4. 4. velj

    This VC firm once pledged to never invest in health care. Now it’s investing $750 million more in the space via

    3 proslijeđena tweeta 9 korisnika označava da im se sviđa
    Poništi
  5. proslijedio/la je Tweet
    3. velj

    Your periodic reminder that all of coverage lives here:

    1 reply 9 proslijeđenih tweetova 14 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  6. proslijedio/la je Tweet
    1. velj

    A top WHO officials told STAT Saturday that "there's enough evidence" to suggest that the new "can still be contained."

    1 reply 12 proslijeđenih tweetova 15 korisnika označava da im se sviđa
    Poništi
  7. proslijedio/la je Tweet
    31. sij

    sets price of peanut allergy drug at $890/month (wholesale acquisition cost)

    11 replies 31 proslijeđeni tweet 62 korisnika označavaju da im se sviđa
    Poništi
  8. proslijedio/la je Tweet
    31. sij

    BREAKING: The United States is closing its borders to foreigners who have set foot in China in the last two weeks, and declaring a public health emergency over the coronavirus outbreak

    9 proslijeđenih tweetova 10 korisnika označava da im se sviđa
    Poništi
  9. proslijedio/la je Tweet
    31. sij

    Banning travel from China in response to the is a *bad* idea, according to public health experts. and explain:

    1 reply 8 proslijeđenih tweetova 6 korisnika označava da im se sviđa
    Poništi
  10. proslijedio/la je Tweet
    31. sij

    I've counted at least a dozen examples of fathers, mothers, siblings etc. leading drug companies to develop treatments for their loved ones rare diseases, but I wanted to take a look and see if they're moving the needle. Here's what I found.

    4 proslijeđena tweeta 3 korisnika označavaju da im se sviđa
    Poništi
  11. 30. sij

    Just now: CDC confirms first known case of person-to-person spread of new coronavirus in U.S.

    3 proslijeđena tweeta 2 korisnika označavaju da im se sviđa
    Poništi
  12. 30. sij

    "'Mark! Over here!' one guest shouted. 'Sweet Jesus,' another murmured." What a delightful start to a story on Walmart's very serious push into health care.

    I took a deep dive into Walmart's effort to build out primary care clinics. Feat. interviews with Walmart Health execs on their strategy, new details on the placement/design of clinics, and a Mark Wahlberg appearance.
    Prikaži ovu nit
    3 korisnika označavaju da im se sviđa
    Poništi
  13. proslijedio/la je Tweet
    30. sij

    Rubius has dosed the first patient in its PKU Phase 1 study. Reminder the timeline on this, maintained well into late 2019, was an early readout by end of last year. The biotech now isn't putting out a timeline on initial data. PR:

    1 proslijeđeni tweet 3 korisnika označavaju da im se sviđa
    Poništi
  14. 29. sij

    I last checked in with Lyra about 6 months ago. At the time, the company's CEO said its phase 2 study for a long-acting nasal spray for (very!) stuffy noses should read out toward the end of this year.

    1 korisnik označava da mu se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  15. 29. sij

    Saw an SEC filing from Lyra Therapeutics on Monday, and yep — the company has indeed raised a $30 million series C.

    1 reply 1 korisnik označava da mu se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  16. proslijedio/la je Tweet
    29. sij

    The FDA wants to know how Instagram influencers sway patient views on medicines via

    11 proslijeđenih tweetova 7 korisnika označava da im se sviđa
    Poništi
  17. 29. sij

    Five venture capital firms — including F-Prime and Polaris — have signed a pledge to bring the proportion of women on their portfolio companies' boards up to 25% by 2022. via

    12 proslijeđenih tweetova 27 korisnika označava da im se sviđa
    Poništi
  18. 28. sij

    Akcea announced positive phase 2 results today from the program it licensed to Pfizer back in October. Pfizer "will determine strategies for potential future development of AKCEA-ANGPTL3-LRx,” per the release.

    1 proslijeđeni tweet 1 korisnik označava da mu se sviđa
    Poništi
  19. proslijedio/la je Tweet
    28. sij

    On a confusing, rapidly evolving issue, this, from and , is super clear:

    2 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
    Poništi
  20. proslijedio/la je Tweet
    27. sij

    Not going to try to best the headline on this story: "The gurus of sperm." But will tell you it's a colorful look at a company trying to take a Y-chromosome-centric approach to fertility problems. Yertle the Turtle appears. via

    6 proslijeđenih tweetova 14 korisnika označava da im se sviđa
    Poništi
  21. 27. sij

    (We also saw some firms raise opportunity funds specifically for the purpose of investing in later rounds, no?)

    Prikaži ovu nit
    Prikaži ovu nit
    Poništi

@sheridan_kate još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·